Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TAK 079

Drug Profile

TAK 079

Alternative Names: Anti-CD38 mAb; TAK-079

Latest Information Update: 15 Jun 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Takeda
  • Class Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Myasthenia gravis
  • Phase I/II Multiple myeloma
  • Phase I Systemic lupus erythematosus
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 29 May 2020 Updated adverse events and efficacy data from a phase I trial in Multiple myeloma presented at the 56th Annual Meeting of the American Society of Clinical Oncology (ASCO-2020)
  • 20 Feb 2020 Millennium Pharmaceuticals plans a phase II trial for Idiopathic thrombocytopenic purpura in April 2020 (SC, Injection) (EudraCT2019-004103-12) (NCT04278924)
  • 06 Jan 2020 Phase-II clinical trials in Myasthenia gravis in USA (SC) (NCT04159805)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top